Last updated on June 2017

SOM230 Ectopic ACTH-producing Tumors


Brief description of study

The purpose of this prospective open-label phase II study, is to evaluate the efficacy of pasireotide twice daily subcutaneous injections for normalizing 24 hour urine free cortisol in patients with ectopic ACTH-producing tumors as measured by the proportion of patients achieving normal UFC at the end of the study period.

Clinical Study Identifier: NCT02780882

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Ning-Ai Liu, MD, PhD

Cedars-Sinai Medical Center
Los Angeles, CA United States
  Connect »